GT BIOPHARMA INC (GTBP) Stock Price, Quote, News and Overview
NASDAQ:GTBP - Nasdaq - US36254L3087 - Common Stock - Currency: USD
GTBP Quote, Performance and Key Statistics
GT BIOPHARMA INC
NASDAQ:GTBP (2/5/2025, 8:04:02 PM)
2.27
+0.07 (+3.18%)
The current stock price of GTBP is 2.27 USD. In the past month the price decreased by -24.08%. In the past year, price decreased by -52.71%.
GTBP Latest News, Press Releases and Analysis
GT Biopharma Reports Third Quarter 2024 Financial Results
GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for...
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company...
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company...
GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024
GT Biopharma just reported results for the second quarter of 2024.
GTBP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.95 | 338.85B | ||
| AMGN | AMGEN INC | 15.53 | 165.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 957.73 | 125.79B | ||
| GILD | GILEAD SCIENCES INC | 22.49 | 124.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.7 | 78.76B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.64B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.34B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.26B | ||
| NTRA | NATERA INC | N/A | 23.37B | ||
| BIIB | BIOGEN INC | 8.91 | 21.21B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.55 | 15.81B |
Related stock screener links
About GTBP
Company Profile
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 2 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The firm is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.
Company Info
GT BIOPHARMA INC
315 Montgomery Street, 10Th Floor
San Francisco CALIFORNIA 90212 US
CEO: Anthony J. Cataldo
Employees: 2
Company Website: https://www.gtbiopharma.com/
Phone: 18003049888
GTBP FAQ
What is the stock price of GTBP?
The current stock price of GTBP is 2.27 USD.
What is the symbol for GT BIOPHARMA INC stock?
The exchange symbol of GT BIOPHARMA INC is GTBP and it is listed on the Nasdaq exchange.
On which exchange is GTBP stock listed?
GTBP stock is listed on the Nasdaq exchange.
Is GTBP a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for GTBP, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of GTBP.
Does GTBP stock pay dividends?
GTBP does not pay a dividend.
What is the Price/Earnings (PE) ratio of GTBP?
GTBP does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.13).
What is the Short Interest ratio of GTBP stock?
The outstanding short interest for GTBP is 9.54% of its float.
GTBP Technical Analysis
GTBP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GTBP. GTBP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GTBP Financial Highlights
Over the last trailing twelve months GTBP reported a non-GAAP Earnings per Share(EPS) of -7.13. The EPS decreased by 53.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.22% | ||
| ROE | -181.4% | ||
| Debt/Equity | 0 |
GTBP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GTBP. The Buy consensus is the average rating of analysts ratings from 7 analysts.